The pathological phenotype of low-risk MDS patients, especially MDS-RA and RARs sub-types, is mainly limited to erythroid cell injury, and their erythroid cell apoptosis begins in the early stage of stem cells. This evidence concerns the gene RARS1 and myelodysplastic syndrome.